XML 31 R14.htm IDEA: XBRL DOCUMENT
v3.22.4

REVENUE | 12 Months Ended
--- | ---
Dec. 31, 2022
REVENUE |
REVENUE | NOTE 8 - REVENUE The following table summarizes the Company’s disaggregation of revenues: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Year Ended December 31,
(U.S. dollars in thousands) | 2020 | ​ | 2021 |  | 2022
Pfizer | $ | 8,105 | ​ | $ | 10,160 | ​ | $ | 12,403
Brazil | $ | 8,000 | ​ | $ | 6,400 | ​ | $ | 9,452
Chiesi | ​ | 131 | ​ | $ | 189 | ​ | $ | 3,437
Total revenues from selling goods | $ | 16,236 | ​ | $ | 16,749 | ​ | $ | 25,292
Revenues from license and R&D services | $ | 46,662 | ​ | $ | 21,601 | ​ | $ | 22,346
​ During the year ended December 31, 2021, and following the CRL received from the FDA and other understandings with Chiesi, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in reduced revenues recognized in respect of this performance obligation in 2021.

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration